


# NANONEUROSCIENCES NEWSLETTER

## A YEAR OF INNOVATION - UNLOCKING THE FUTURE OF GLAUCOMA TREATMENT

As we begin the second quarter of 2025, we want to take a moment to reflect on the strong progress we've made at [NanoNeurosciences, Inc.](#) Since our last newsletter in December 2024, we've translated our vision into tangible milestones - laying a strong foundation for the future as we continue advancing transformative solutions in nanomedicine.

### Fostering Strong Connections with Local and Global Biotech Ecosystems

NanoNeurosciences, Inc. participated in various events the 1<sup>st</sup> quarter of 2025.



BioFlorida Hosted South Florida Life Sciences Showcase



BiInnovation Greece Hosted High-Impact Strategy Meeting on Advancing Biotech Entrepreneurship in Greece.



Drs. Zois Syrgiannis, Greg Roumeliotis, Salvatore Incontro and Matias Alvarez-Saavedra (from left to right) at the R&D Department of NNS (March 2025).



UF Innovate | Accelerate at Sid Martin Biotech Incubator, Alachua, Florida (R&D Laboratories).

### Scientific Milestones

***Our research team has made significant strides in the first quarter of 2025:***

- **Intellectual Property 1 (IP1) is filled:** We recently filed our first provisional patent application in the US, entitled: *METHODS AND COMPOSITIONS FOR DISCRETE SELF-ASSEMBLED PEPTIDE NANOSTRUCTURES*, which focuses on a new composition of matter involving novel peptide sequences that self-assemble into nanocarriers.
- **Screening of more than 100 candidates:** We synthesized and characterized more than 100 nanostructure-forming candidates.
- **Biochemical Evaluation of Lead Candidates:** We successfully biochemically evaluated and selected our lead glaucoma-reversing candidates.
- **Lead Candidate Stability Assays:** Our lead candidates were tested in aqueous buffer and rabbit aqueous humor at 37°C for 60 days, and these novel nanostructures present 100% integrity and biochemical activity.

## Strategic Partnerships and Business Achievements

***To accelerate our progress and maximize our impact, NanoNeurosciences has formed strategic partnerships with key industry leaders. These collaborations enhance our ability to translate cutting-edge research into real-world solutions and bring innovative nanomedicine technologies closer to the patients who need them most:***

- **Lions World Vision Institute:** We are excited to announce our collaboration with **LWVI**, which provides us with access to human ocular cells, both healthy and glaucomatous. Through this partnership, we will gain access to advanced techniques that support the evaluation of our novel nanomedicines, significantly enhancing our research in ocular therapeutics.
- **Efficacy Experiments Partnerships:** As part of our network, we initiated a collaboration with **Iris Pharma**, a leading contract research organization (CRO) dedicated to ophthalmic research. Iris Pharma supports us in conducting preclinical efficacy experiments in rabbit animal models. This partnership plays a key role in advancing our nanomedicine-based therapies for the treatment of Glaucoma.
- **Histology Experiments Partnership:** We are proud to engage with **Pharmaseed Ltd.**, a global certified pre-clinical Contract Research Organization (CRO) specializing in translational projects across all development stages. With their expertise, Pharmaseed supports us in conducting multidisciplinary and complex studies, including advanced histological experiments, to evaluate the biodistribution of our lead candidates.
- **Government Support:** We have submitted a National Institute of Health (NIH), Small Business Innovation Research (SBIR) grant to further propel our research and development.
- **Collaboration with Gerhard Bauer:** We are thrilled to announce that we will be engaging with **Gerhard Bauer**, a renowned expert in GMP manufacturing and the formulation of novel therapeutic products. With over 15 years as Director of the UC Davis GMP facility, Gerhard started serving as a key advisor, supporting the transition of our nanomedicine products from the lab bench to the clinic. His expertise will also guide us through the complex regulatory landscape, ensuring a strong foundation for successful clinical trials.

***As we enter a transformative year, we do so with deep sense of optimism and excitement. Together, we have established a strong foundation for meaningful advancements in the field of nanomedicine—especially for patients living with open-angle glaucoma.***

***We are sincerely grateful for your continued trust and support. It is this shared commitment that drives us to push the boundaries of science and deliver innovative solutions with the potential to improve the lives of millions around the world.***



Gerhard Bauer.

**Your collaboration and support inspire and drive us forward!**

**The NanoNeurosciences Team**

